Brii Biosciences Closes US$155 Million Series C Financing

23 Mar, 2021

Brii Biosciences Closes US$155 Million Series C Financing
Photo by Nastuh Abootalebi on Unsplash

– Brii Bio, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burden, today announced completion of a Series C financing of US$155m.
– The financing was led by Invesco Developing Markets Fund, with significant additional funding provided by GIC and another global leading investment management organization, followed by Lake Bleu Capital and an Asia-based leading investment organization, as well as three current investors.
– Proceeds from the financing will be used to advance Brii Bio’s broad infectious diseases pipeline as well as the company’s CNS program.
– Brii Bio is currently conducting clinical studies in multiple infectious diseases, and is preparing to enter clinical-stage research in diseases of the central nervous system.

Biotechnology Health Care Innovation Management North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: